Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

The U.S. is having its worst year for measles spread in more than three decades, with a total of 1,288 cases nationally and ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...

The dramatic rise of weight-loss drugs such as Ozempic and Mounjaro had upended WeightWatchers' business model ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...